605 Page 1 23-Sep-2026To Company Name/SchemeACN/ARSN1. Details of substantial holder (1)NameACN/ARSN (if applicable)The holder ceased to be a substantial holder on21/09/2026The previous notice was given to the company on13/08/2026The previous notice was dated11/08/20262. Changes in relevant...
Ceasing to be a substantial holder
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Mesoblast
- Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
- Mesoblast Reports Substantial Revenue Growth to US$120M
- MSB Annual Financial Results and Operational Update
- Annual Financial Results Presentation
- Preliminary Final Report including Appendix 4E
Later from Mesoblast
- FDA Approves New Potency Assay for Commercial Ryoncil
- Becoming a substantial holder
- Appendix 4G and Corporate Governance Statement
- Notice of Annual General Meeting and Proxy Form
- Annual Report to Shareholders
